Oncorena AB is a biotechnology startup headquartered in Lund, Sweden, founded in 2011. The company is focused on developing a first-in-class treatment for advanced renal cancer, utilizing a natural substance as the basis for their breakthrough therapy. Oncorena has completed all preclinical studies and is now entering early-stage clinical development, with the goal of confirming the potent anti-tumor activity of their drug candidate, which is based on the natural substance orellanine. The startup recently received a kr66.00M Venture Round investment on 23 December 2021, with participation from notable investors including HealthCap, Linc AB, and Fåhraeus Startup and Growth.
Oncorena AB
Developing a first-in-class treatment for advanced renal cancer
Founded 2011
Sweden
10 employees
Venture round
Total: $80.50M
Biotechnology, Health Care +1
Sweden
10 employees
Venture round
Total: $80.50M
Biotechnology, Health Care +1
General Information
Company Name
Oncorena AB
Founded Year
2011
Location
Sweden
Sweden
Employees
10
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Venture round
BounceWatch is an independent company data service, not affiliated with Oncorena AB. To contact Oncorena AB, visit oncorena.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Oncorena AB compare?
A PDF of Oncorena AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Oncorena AB soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Sweden Market
Biotechnology
About Oncorena AB
Business keywords: Oncorena, renal cancer treatment, advanced kidney cancer, drug development, oncology, clinical trials, preclinical studies, cancer therapy, Swedish biotech, Lund, orellanine, anti-tumor activity, early-stage clinical development, drug candidate
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | kr66.00M | 3 |
|
23 Dec 2021 |
| Venture Round | kr14.50M | 2 |
|
22 Nov 2018 |
Oncorena AB Alternatives & Competitors
View All Alternatives
Oncorena AB vs
Cybrexa Therapeutics
United States
Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...
Series B
11 employees
Biotechnology, Health and Wellness
Oncorena AB vs
Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition
Series A
Biotechnology, Health Care
Oncorena AB vs
Jounce Therapeutics, Inc.
United States
Daring to create a world immune to cancer.
Post-IPO Equity
18 employees
Biotechnology, Health and Wellness
FAQ About Oncorena AB
Developing a first-in-class treatment for advanced renal cancer
Oncorena AB was founded in 2011.
Oncorena AB is headquartered in Sweden.
Oncorena AB operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Oncorena, renal cancer treatment, advanced kidney cancer and drug development.
Oncorena AB has approximately 10 employees.
Oncorena AB has completed 2 funding rounds, raising a total of $80.50M. The latest funding stage is Venture round.
Top alternatives and competitors to Oncorena AB include Cybrexa Therapeutics, Cavion, Jounce Therapeutics, Inc., Cinclus Pharma, Pacylex Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oncorena AB and Cybrexa Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Oncorena AB, https://bouncewatch.com/company/oncorena-ab, updated 2 December 2024. When citing, please name BounceWatch and link this page.
